[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337815-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337815-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrated-analysis-of-the-role-of-prset-domain-14-in-gastric-cancer","Integrated analysis of the role of PR/SET domain 14 in gastric cancer","","Gastric cancer remains a leading global malignancy, and advanced-stage diagnosis often limits effective treatment options. This study investigates PRDM14, known for carcinogenic potential in other cancers but poorly defined in gastric cancer. Using pan-cancer expression analysis and cellular/patient measurements (qPCR, western blotting, immunohistochemistry), the work tests PRDM14 function via gene silencing and builds a prognostic model. It predicts drug-response associations via Connectivity Map and GDSC, validating clinical relevance through survival nomograms, pathways, and drug sensitivity correlations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-analysis-of-the-role-of-prset-domain-14-in-gastric-cancer/337815/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-analysis-of-the-role-of-prset-domain-14-in-gastric-cancer/337815.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was PRDM14 investigated in gastric cancer?","Question",{"text":63,"@type":64},"PRDM14 shows carcinogenic roles in other cancers, but its function in gastric cancer was not clearly established. The study targets PRDM14’s expression, regulation, and clinical significance in gastric cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was PRDM14 expression and function assessed?",{"text":68,"@type":64},"PRDM14 expression was analyzed using pan-cancer approaches and measured in cells and patient tissues with qPCR, western blotting, and immunohistochemistry. Functional effects were evaluated by silencing PRDM14 and examining apoptosis, cell-cycle changes, and effects on growth and migration.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find regarding prognosis and drug response?",{"text":72,"@type":64},"A PRDM14-derived differential gene prognostic model was validated to predict patient outcomes, and nomograms quantified survival probability using age, sex, and PRDM14 risk score. PRDM14 was also positively correlated with sensitivity to small-molecule drugs including TPCA-1, PF-56,227, mirin, and linsitinib.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337815,1790568111,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Li etal. BMC Cancer (2024) 24:685 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12424-1](https://doi.org/10.1186/s12885-024-12424-1)  \nRESEARCH Open Access  \nIntegrated analysis of the role of PR/SET domain 14 in gastric cancer  \nXiao Li 1, Cong Wang 1, Youcai Wang 1, Xiaobing Chen 1, Zhi Li 1, Jianwei Wang2* andYingjun Liu 1*  \nAbstract  \nBackground Gastric cancer is one of the most common tumors worldwide, and most patients are deprived of treatment options when diagnosed at advanced stages. PRDM14 has carcinogenic potential in breast and non-small cell lung cancer. however, its role in gastric cancer has not been elucidated.  \nMethods We aimed to elucidate the expression of PRDM14 using pan-cancer analysis. We monitored the expression of PRDM14 in cells and patients using quantitative polymerase chain reaction, western blotting, and immunohistochemistry. We observed that cell phenotypes and regulatory genes were influenced by PRDM14 by silencing PRDM14 . We evaluated and validated the value of the PRDM14-derived prognostic model. Finally, we predicted the relationship between PRDM14 and small-molecule drug responses using the Connectivity Map and The Genomics of Drug Sensitivity in Cancer databases.  \nResults PRDM14 was significantly overexpressed in gastric cancer, which identified in cell lines and patients’ tissues. Silencing the expression of PRDM14 resulted in apoptosis promotion, cell cycle arrest, and inhibition of the growth and migration of GC cells. Functional analysis revealed that PRDM14 acts in epigenetic regulation and modulates multiple DNA methyltransferases or transcription factors. The PRDM14-derived differential ly expressed gene prognostic model was validated to reliably predict the patient prognosis. Nomograms (age, sex, and PRDM14-risk score) were used to quantify the probability of survival. PRDM14 was positively correlated with sensitivity to smallmolecule drugs such asTPCA-1, PF-56,227, mirin, and linsitinib.  \nConclusions Collectively, our findings suggest that PRDM14 is a positive regulator of gastric cancer progression. Therefore, it may be a potential therapeutic target for gastric cancer.  \nKeywords Gastric cancer, PRDM14, Apoptosis, NANOG, Prognostic model  \n*Correspondence: Jianwei Wang [wjw725@126.com](wjw725@126.com)[ ](wjw725@126.com)Yingjun Liu [yingjun6727@sina.com](yingjun6727@sina.com)  \n1Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China  \n2School of Computer and Artificial Intelligence, Zhengzhou University, Zhengzhou, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nLi et al. BMC Cancer (2024) 24:685  \nIntroduction  \nGastric cancer (GC) is a prevalent gastrointestinal malignancy, ranking fifth in incidence and fourth in mortality worldwide [1]. Despite advancements in early screening and anti-cancer strategies, late-stage diagnoses","cbCairMHSrmMZtaF","https://ap.wps.com/l/cbCairMHSrmMZtaF","pdf",8794401,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why was PRDM14 investigated in gastric cancer?\",\"answer\":\"PRDM14 shows carcinogenic roles in other cancers, but its function in gastric cancer was not clearly established. The study targets PRDM14’s expression, regulation, and clinical significance in gastric cancer.\"},{\"question\":\"How was PRDM14 expression and function assessed?\",\"answer\":\"PRDM14 expression was analyzed using pan-cancer approaches and measured in cells and patient tissues with qPCR, western blotting, and immunohistochemistry. Functional effects were evaluated by silencing PRDM14 and examining apoptosis, cell-cycle changes, and effects on growth and migration.\"},{\"question\":\"What did the study find regarding prognosis and drug response?\",\"answer\":\"A PRDM14-derived differential gene prognostic model was validated to predict patient outcomes, and nomograms quantified survival probability using age, sex, and PRDM14 risk score. PRDM14 was also positively correlated with sensitivity to small-molecule drugs including TPCA-1, PF-56,227, mirin, and linsitinib.\"}]","Integrated analysis of the role of PR/SET domain 14 in gastric cancer | PDF",1790020782,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/772894df6a558e006cf06faf190a7b08.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75cb8fbff0c9043338766fac08cb7db4.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d1b5d04bf2b336a111177215ad52a66.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/020a8f656d3f58695c51e1b568e0c9b2.webp",980,1306]